Palbociclib-The First of a New Class of Cell Cycle Inhibitors
Marcus Schmidt1, Martin Sebastian2
1Department of Obstetrics and Gynecology, University Medical Center Mainz, Langenbeckstr. 1, 55131, Mainz, Germany. marcus.schmidt@unimedizin-mainz.de.
Abstract:
During the last decades, much has been learned about with cyclin-dependent kinases (CDK) playing a pivotal role in the cell cycle regulation. CDK4/6 is the key regulator of the G1-S transition. Palbociclib (PD 0332991, Ibrance®) is the first oral CDK4/6 inhibitor showing a substantially improved median progression-free survival (PFS) in advanced estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer. This PFS prolongation was seen both with letrozole as first-line therapy (24.8 vs. 14.5 months [PALOMA 2]) and with fulvestrant in endocrine pretreated patients (9.2 vs. 3.8 months [PALOMA-3]). The main toxicity is neutropenia due to cell cycle arrest which can be easily managed with dose interruption or dose reduction leading to a favorable safety profile with delayed deterioration of global quality of life (QoL). Palbociclib is approved by the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) for ER-positive/HER2-negative advanced breast cancer. Despite the well-understood mode of action of palbociclib, predictive biomarkers are not yet defined. In conclusion, inhibition of CDK4/6 using palbociclib in combination with endocrine therapy is an efficient and well-tolerated treatment option in ER-positive/HER2-negative advanced breast cancer. Ongoing clinical trials are investigating the role of palbociclib in early breast cancer as well as in other types of cancer.
Insights
Palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, significantly improves progression-free survival in advanced ER-positive/HER2-negative breast cancer when combined with endocrine therapy. This treatment is well-tolerated, with manageable side effects like neutropenia.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Cyclin-dependent kinases (CDKs) regulate cell cycle progression, with CDK4/6 being crucial for the G1-S phase transition.
- Dysregulation of cell cycle control is a hallmark of cancer, making CDK inhibitors a target for cancer therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of palbociclib, an oral CDK4/6 inhibitor, in combination with endocrine therapy for advanced ER-positive/HER2-negative breast cancer.
- To assess the impact of palbociclib on progression-free survival (PFS) and overall quality of life (QoL).
Main Methods:
- Clinical trials (PALOMA-2 and PALOMA-3) involving patients with advanced ER-positive/HER2-negative breast cancer.
- Palbociclib administered orally in combination with letrozole (first-line) or fulvestrant (endocrine pretreated).
Main Results:
- Palbociclib significantly prolonged PFS compared to placebo in both first-line (24.8 vs. 14.5 months) and endocrine-pretreated (9.2 vs. 3.8 months) settings.
- The primary toxicity observed was neutropenia, which was manageable through dose adjustments, leading to a favorable safety profile and delayed QoL deterioration.
Conclusions:
- Palbociclib in combination with endocrine therapy is an effective and well-tolerated treatment for advanced ER-positive/HER2-negative breast cancer.
- Further research is ongoing to explore palbociclib's role in early-stage breast cancer and other cancer types, with a need for predictive biomarkers.
More Related Videos
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
What is the Cell Cycle?
What is the Cell Cycle?
Lytic Cycle of Bacteriophages
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System
